New Uses for Lithium and Anticonvulsants

Harvard Review of Psychiatry

Volumn 11, Issue 5, 2003, Pages 230-244

  Salzman, Carl ^a  

^a MASSACHUSETTS MENTAL HEALTH CENTER   (United States)

Author keywords

Aggression; Anticonvulsant; Augmentation; Bipolar; Depression; Lithium; Monotherapy; Schizophrenia

Indexed keywords

ALPRAZOLAM; AMFEBUTAMONE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BENZODIAZEPINE; CARBAMAZEPINE; CLONAZEPAM; FLUOXETINE; FLUPENTIXOL; GABAPENTIN; HALOPERIDOL; LAMOTRIGINE; LITHIUM; LITHIUM CARBONATE; NEUROLEPTIC AGENT; OLANZAPINE; PAROXETINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; TIAGABINE; TOPIRAMATE; VALPROATE SEMISODIUM; VIGABATRIN;

AGGRESSION; AGITATION; AGORAPHOBIA; ALCOHOL WITHDRAWAL; ALCOHOLISM; ANGER; ANXIETY DISORDER; ASPERGER SYNDROME; AUTISM; BINGE EATING DISORDER; BIPOLAR DISORDER; CLASSIFICATION; CLINICAL TRIAL; COCAINE DEPENDENCE; CONFERENCE PAPER; DRUG EFFICACY; HUMAN; MENTAL DISEASE; MONOTHERAPY; MOOD DISORDER; PANIC; PRIORITY JOURNAL; SCHIZOPHRENIA; SOCIAL PHOBIA; SOMATIZATION; TARDIVE DYSKINESIA; VISUAL HALLUCINATION; WITHDRAWAL SYNDROME;

EID: 0242317832     PISSN: 10673229     EISSN: None     Source Type: Journal    
DOI: 10.1080/hrp.11.5.230.244     Document Type: Conference Paper

References (204)

1. Schou M. The range of non-psychiatric uses of lithium. In: Johnson FN, ed. Handbook of lithium therapy. Baltimore, MD: University Park Press, 1980:73-9.
2. Goodwin FK, Jamison KR, eds. Manic-depressive illness. New York: Oxford University Press, 1990.
3. McElroy SL, Keck PE, Pope HG, Harrison JI. Valproate in psychiatric disorders: literature review and clinical guidelines. J Clin Psychiatry 1989;50(suppl 3):23-9.
4. Charney DS, Berman RM, Miller HL. Treatment of depression. In: Schatzberg AF, Nemeroff CB, eds. The American Psychiatric Press textbook of psychopharmacology. 2nd ed. Washington, DC: American Psychiatric Press, 1998:705-31.
5. Davis LL, Ryan W, Adinoff B, Petty F. Comprehensive review of the psychiatric uses of valproate. J Clin Psychopharmacol 2000;20(suppl 1):1S-17S.
6. Ghaemi SN, Gaughan S. Novel anticonvulsants: a new generation of mood stabilizers? Harv Rev Psychiatry 2000;8:1-7.
7. Baldessarini RJ, Tondo L, Hennen J, Viguera AC. Is lithium still worth using? An update of selected recent research. Harv Rev Psychiatry 2002;10:59-75.
8. Post RM, Uhde TW, Roy-Byrne PP, Joffe RT. Antidepressant effects of carbamazepine. Am J Psychiatry 1986;143:29-34.
9. Davis LL, Kabel D, Patel D, Choate AD, Foslien-Nash C, Gurguis NM, et al. Valproate as an antidepressant in major depressive disorder. Psychopharmacol Bull 1996;32:647-52.
10. Lambert PA. Acute and prophylactic therapies of patients with affective disorders using valpromide (dipropylacetamide). In: Emrich HM, Okuma T, Muller AA, eds. Anticonvulsants in affective disorders. Amsterdam: Excerpta Medica, 1984:33-44.
11. Deltito JA, Levitan J, Damore K, Hajal F, Fambenedetti M. Naturalistic experience with the use of divalproex sodium on an inpatient unit for adolescent psychiatric patients. Acta Psychiatr Scand 1998;97:236-40.
12. Pies R, Adler DA, Ehrenberg BL. Sleep disorders and depression with atypical features: response to valproate. J Clin Psychopharmacol 1989;9:352-7.
13. Kemp LI. Sodium valproate as an antidepressant. Br J Psychiatry 1992;160:121-3.
14. Kusumaker V, Yatham LN. An open study of lamotrigine in refractory bipolar depression. Psychiatry Res 1997;72:145-8.
15. Calabrese JR, Bowden CL, McElroy SL, Cookson K, Anderson J, Keck PE, et al. Spectrum of activity of lamotrigine in treatment-refractory bipolar disorder. Am J Psychiatry 1999;156:1019-23.
16. Calabrese JR, Bowden CL, Sachs GS, Ascher JA, Monaghan E, Rudd GD. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. J Clin Psychiatry 1999;60:79-88.
17. Frye MA, Ketter TA, Kimbrell TA, Dunn RT, Speer AM, Osuch EA, et al. A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. J Clin Psychopharmacol 2000;20:607-13.
18. Suppes T, Brown ES, McElroy SL, Keck PE Jr, Nolen W, Kupka R, et al. Lamotrigine for the treatment of bipolar disorder: a clinical case series. J Affect Disord 1999;53:95-8.
19. Hoopes S. Lamotrigine in the treatment of bipolar depression and other affective disorders: clinical experience in 218 patients [Abstract]. Bipolar Disord 1999;1(suppl):35.
20. Yatham LN, Kusumakar V, Calabrese JR, Rao R, Scarrow G, Kroeker G. Third generation anticonvulsants in bipolar disorder: a review of efficacy and summary of clinical recommendations. J Clin Psychiatry 2002;63:275-83.
21. Young LT, Robb JC, Patellis-Siotis I, MacDonald C, Joffe RT. Acute treatment of bipolar depression with gabapentin. Biol Psychiatry 1997;42:851-3.
22. Rocha F, Hara C. Lamotrigine augmentation in unipolar depression. Int Clin Psychopharmacol 2003;18:97-9.
23. Ghaemi SN, Katzow JJ, Desai SP, Goodwin FK. Gabapentin treatment of mood disorders: a preliminary study. J Clin Psychiatry 1998;59:426-9.
24. Ghaemi SN, Goodwin FK. Gabapentin treatment of the non-refractory bipolar spectrum: an open case series. J Affect Disord 2001;65:167-71.
25. Obrocea GV, Dunn RM, Frye MA, Ketter TA, Luckenbrough DA, Levencj GS, et al. Clinical predictors of response to lamotrigine and gabapentin monotherapy in refractory affective disorders. Biol Psychiatry 2002;51:253-60.
26. Fawcett JA. Lithium combinations in acute and maintenance treatment of unipolar and bipolar depression. J Clin Psychiatry 2003;64(suppl 5):32-7.
27. Rouillon F, Gorwood P. The use of lithium to augment antidepressant medication. J Clin Psychiatry 1998;59(suppl 5):32-9.
28. Dietrich DE, Emrich HM. The use of anticonvulsants to augment antidepressant medication. J Clin Psychiatry 1998;59(suppl 5):51-8.
29. Rybakowski JK, Susalska S, Chlopoca-Wozniak M. Potentiation of antidepressants with lithium or carbamazepine in treatment-resistant depression. Neuropsychobiology 1999;40:134-9.
30. Kusumaker V, Yatham LN. Lamotrigine treatment of rapid cycling bipolar disorder [Letter]. Am J Psychiatry 1997;154:1171-2.
31. Norman C, Hummer B, Schärer LO, Hörn M, Walden J. Lamotrigine as adjunct to paroxetine in acute depression: a placebo-controlled, double-blind study. J Clin Psychiatry 2002;63:337-44.
32. Barbee JG, and Jamhour NJ. Lamotrigine as an augmentation agent in treatment-resistant depression. J Clin Psychiatry 2002;63:737-41.
33. Maltese TM. Adjunctive lamotrigine treatment for major depression. Am J Psychiatry 1999;156:1833.
34. Hurley SC. Lamotrigine update and its use in mood disorders. Ann Pharmother 2002;36:860-73.
35. Barbosa L, Berk M, Vorster M. A double-blind, randomized, placebo-controlled trial of augmentation with lamotrigine or placebo in patients concomitantly treated with fluoxetine for resistant major depressive episodes. J Clin Psychiatry 2003;64:403-7.
36. Dave M. Antidepressant augmentation with valproate. Depression 1995;3:157-8.
37. Corrigan FM. Sodium valproate augmentation of fluoxetine or fluvoxamine effects. Biol Psychiatry 1992;31:1178-9.
38. Chengappa KNR, Gershon S, Levine J. The evolving role of topiramate among other mood stabilizers in the management of bipolar disorder. Bipolar Disord 2001;3:215-32.
39. Janicak PG, Davis JM, Preskorn SH, Ayd FJ Jr. Principles and practice of psychopharmacology. 2nd ed. Baltimore, MD: Williams & Wilkins, 1993.
40. Lenox RH, Manji HK. Lithium. In: Schatzberg AF, Nemeroff CB, eds. The American Psychiatric Press textbook of psychopharmacology. 2nd ed. Washington, DC: American Psychiatric Press, 1998:379-429.
41. Shopsin B, Kim SS, Gershon S. A controlled study of lithium vs. chlorpromazine in acute schizophrenics. Br J Psychiatry 1971;119:435-40.
42. Biederman J, Lerner Y, Belmaker RH. Combination of lithium carbonate and haloperidol in schizo-affective disorder. A controlled study. Arch Gen Psychiatry 1979;36:327-33.
43. Chong S-A, Lee E-L, Liow P-H. Augmentation of risperidone with valproic acid [Letter]. J Clin Psychiatry 1998;59:430.
44. Okuma T, Yanashita I, Takahashi R, Itoh H, Otsuki S, Watanabe S, et al. A double-blind study of adjunctive carbamazepine versus placebo on excited states of schizophrenic and schizoaffective disorders. Acta Psychiatr Scand 1989;80:250-9.
45. Leucht S, McGrath J, White P, Kissling W. Carbamazepine for schizophrenia and schizoaffective psychosis. Cochrane Database Syst Rev 2002;3:CD001258.
46. Wirshing DA. [Review of] Leucht S, McGrath J, White P, Kissling W. Carbamazepine augmentation for schizophrenia: how good is the evidence? [J Clin Psychiatry 2002;63:218-24]. J Psychotic Disorders: Reviews & Commentaries 2002;5(1):5.
47. Wirshing DA. [Review of] Leucht S, McGrath J, White P, Kissling W. Carbamazepine augmentation for schizophrenia: how good is the evidence? [J Clin Psychiatry 2002;63:218-24]. J Psychotic Disorders: Reviews & Commentaries 2002;5(1):5.
48. Linnoila M, Viukari M, Hietala O. Effect of sodium valproate on tardive dyskinesia. Br J Psychiatry 1976;129:114-9.
49. Gundurewa VM, Beckmann H, Zimmer R, Ruther E. Effect of valproic acid on schizophrenic syndromes. Drug Res 1980;30:1212-3.
50. Nagao R, Ohshimo T, Mitsunobu K, Sato M, Otsuki S. Cerebrospinal fluid monoamine metabolites and cyclic nucleotides in chronic schizophrenic patients with tardive dyskinesia or drug-induced tremor. Biol Psychiatry 1979;14:509-73.
51. Afaq L, Riaz K, Sedky K, Chung DJ, Vanina Y, el-Mallakh R, et al. Divalproex as a calmative adjunct for aggressive schizophrenia patients. J Ky Med Assoc 2002;100:17-22.
52. Wassef A, Watson DJ, Morrison P, Bryant S, Flack K. Neuroleptic-valproic acid combination in treatment of psychotic symptoms: a three-case report. J Clin Psychopharmacol 1989;9:45-7.
53. Kando JC, Tohen M, Castillo J, Centorrino F. Concurrent use of clozapine and valproate in affective and psychotic disorders. J Clin Psychiatry 1994;55:255-7.
54. Kausen J, Zimmermann P, Funfgeld EW, Klenke D, Henkel H. Effect of a GABA-mimetic drug (sodium valproate) on visually evoked potentials in chronic schizophrenics. Neuropsychobiology 1984;11:59-64.
55. Wassef AA, Hafiz NG, Hampton D, Molloy M. Divalproex sodium augmentation of haloperidol in hospitalized patients with schizophrenia: clinical and economic implications. J Clin Psychopharmacol 2001;21:21-6.
56. Wassef AA, Dott SG, Harris A, Brown A, O'Boyle M, Meyer WJ, et al. Randomized, placebo-controlled pilot study of divalproex sodium in the treatment of acute exacerbations of chronic schizophrenia. J Clin Psychopharmacol 2000;20:357-61.
57. Lautin A, Angrist B, Stanley M, Gershon S, Heckl K, Karobath M. Sodium valproate in schizophrenia: some biochemical correlates. Br J Psychiatry 1980;137:240-4.
58. Ko G, Korpi E, Freed W, Zalcman SJ, Bigelow LB. Effects of valproic acid on behavior and plasma amino acid concentrations in chronic schizophrenic patients. Biol Psychiatry 1985;200:199-228.
59. McElroy SL, Pope HK, Keck PE, Hudson JI. Treatment of psychiatric disorders with valproate: a series of 73 cases. Psychiatr Psychobiol 1988;3:81-5.
60. Fisk GG, York SM. The effect of sodium valproate on tardive dyskinesia revisited. Br J Psychiatry 1987;150:542-6.
61. Anand A, Charney DS, Oren DA, Berman RM, Hu XS, Cappiello A, et al. Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic of N-methyl-D-aspartate receptor antagonists. Arch Gen Psychiatry 2000;57:270-6.
62. Saba G, Dumortier G, Kalalou K, Degrassat K, Glikman J, Januel D. Lamotrigine-clozapine combination in refractory schizophrenia: three cases. J Neuropsychiatry Clin Neurosci 2002;14:86.
63. Kossen M, Selten JP, Kahn RS. Elevated clozapine plasma level with lamotrigine [Letter]. Am J Psychiatry 2001;158:1930.
64. Dursun SM, Deakin JF. Augmenting antipsychotic treatment with lamotrigine or topiramate in patients with treatment-resistant schizophrenia: a naturalistic case-series outcome study. J Psychopharmacol 2001;15:297-301.
65. Dursun SM, McIntosh D, Milliken H. Clozapine plus lamotrigine in treatment-resistant schizophrenia [Letter]. Arch Gen Psychiatry 1999;56:950.
66. Dursun SM, Devarajan S. When treating patients with schizophrenia, what clinical points should be considered if lamotrigine is chosen to augment clozapine? J Psychiatry Neurosci 2001;26:168.
67. Sharma RP, Martis B, Davis JM, Omens R, Janicak PG. Tiagabine, a specific gamma-aminobutyric acid transporter-1 inhibitor, in the treatment of psychosis. J Clin Psychopharmacol 2001;21:347-9.
68. Millson RC, Owen JA, Lorberg GW, Tackaberry L. Topiramate for refractory schizophrenia. Am J Psychiatry 2002;159:675.
69. Buchanan RW, Kreyenbuhl J, Zito JM, Lehman A. Relationship of the use of adjunctive pharmacological agents to symptoms and level of function in schizophrenia. Am J Psychiatry 2002;159:1035-43.
70. Citrome L, Levine J, Allingham B. Utilization of valproate: extent of inpatient use in the New York State Office of Mental Health. Psychiatr Q 1998;69:283-300.
71. Hori H, Terao T, Shiraishi Y, Nakamura J. Treatment of Charles Bonnet syndrome with valproate. Int Clin Psychopharmacol 2000;15:117-9.
72. Paulig M, Mentrup H. Charles Bonnet's syndrome: complete of complex visual hallucinations treated by gabapentin. J Neurol Neurosurg Psychiatry 2001;70:813-4.
73. Chen C-S, Lin S-F, Chong M-Y. Charles Bonnet syndrome and multiple sclerosis [Letter]. Am J Psychiatry 2001;158:1158-9.
74. Sheard MH, Marini JL, Bridges CI, Wagner E. The effects of lithium in impulsive aggressive behavior in man. Am J Psychiatry 1976;133:1409-13.
75. Yudofsky SC, Silver JM, Hales RE. Treatment of agitation and depression. In: Schatzberg AF, Nemeroff CB, eds. The American Psychiatric Press textbook of psychopharmacology. 2nd ed. Washington, DC: American Psychiatric Press, 1998:881-900.
76. Giakas WJ, Seibyl JP, Mazure CM. Valproate in the treatment of temper outbursts [Letter]. J Clin Psychiatry 1990;51:525.
77. Mattes JA. Valproic acid for nonaffective aggression in the mentally retarded. J Nerv Ment Dis 1992;18:601-2.
78. Lindenmayer JP, Kotsaftis A. Use of sodium valproate in violent and aggressive behaviors: a critical review. J Clin Psychiatry 2000;61:123-8.
79. Schatzberg AF. Phenomenology and treatment of agitation. J Clin Psychiatry Monogr 1999;17:12-4.
80. Velikonja M, Heinrich K. Effect of oxcarbazepine (CG 47.680) on affective and schizoaffective symptoms: a preliminary report. In: Emrich HM, Okuma T, Müller AA, eds. Anticonvulsants in affective disorders. New York: Elsevier Science, 1984:208-10.
81. Dale PG. Lithium therapy in aggressive mentally subnormal patients. Br J Psychiatry 1980;137:469-74.
82. Luchins DJ, Dojka D. Lithium and propranolol in aggression and self-injurious behavior in the mentally retarded. Psychopharmacol Bull 1989;25:372-5.
83. Donovan SJ, Stewart JW, Nunes EV, Quitkin FM, Parides M, Daniel W, et al. Divalproex treatment for youth with explosive temper and mood lability: a double-blind, placebo-controlled crossover design. Am J Psychiatry 2000;157:818-20.
84. Sovner R. The use of valproate in the treatment of mentally retarded persons with typical and atypical bipolar disorders. J Clin Psychiatry 1989;50:40-3.
85. Kastner R, Finesmith R, Walch K. Long-term administration of valproic acid in the treatment of affective symptoms in people with mental retardation. J Clin Psychopharmacol 1993;13:448-51.
86. Ruedrich S, Swales TP, Fossaceca C, Toliver J, Rutkowski A. Effect of divalproex sodium on aggression and self-injurious behavior in adults with intellectual disability: a retrospective review. J Intell Disabil Res 1999;43:105-11.
87. Mazure CM, Druss BG, Cellar JS. Valproate treatment of older psychotic patients with organic mental syndromes and behavioral dyscontrol. J Am Geriatr Soc 1992;40:914-6.
88. DeLong R. Children with autistic spectrum disorder and a family history of affective disorder. Dev Med Child Neurol 1994;36:674-87.
89. Dulcan MK, Bregman J, Weller EB, and Weller R. Treatment of childhood and adolescent disorders. In: Schatzberg AF, Nemeroff CB, eds. The American Psychiatric Press textbook of psychopharmacology. 2nd ed. Washington, DC: American Psychiatric Press, 1998:803-50.
90. Hollander E, Dolgoff-Kaspar R, Cartwright C, Rawitt R, Novotny S. An open trial of divalproex sodium in autism spectrum disorders. J Clin Psychiatry 2001;62:530-4.
91. Duggal HS, Dutta S, Sinha VK. Mood stabilizers in Asperger's syndrome. Aust N Z J Psychiatry 2001;35:390.
92. Belsito KM, Law PA, Kirk KS, Landa RJ, Zimmerman AW. Lamotrigine therapy for autistic disorder: a randomized, double-blind, plabebo-controlled trial. J Autism Dev Disorder 2001;31:175-81.
93. Holton A, George K. The use of lithium in severely demented patients with behavioral disturbance. Br J Psychiatry 1985;146:99-100.
94. Marin DB, Greenwald BS. Carbamazepine for aggressive agitation in demented patients [Letter]. Am J Psychiatry 1989;146:805.
95. Gleason RP, Schneider LS. Carbamazepine treatment of agitation in Alzheimer's outpatients refractory to neuroleptics. J Clin Psychiatry 1990;51:115-8.
96. Tariot PN, Erb R, Leibovici A, Podgorski CA, Cox C, Asnis J, et al. Carbamazepine treatment of agitation in nursing home patients with dementia: a preliminary study. J Am Geriatr Soc 1994;42:1160-6.
97. Tariot PN, Erb R, Podgorski CA, Cox C, Patel S, Jakimovich L, et al. Efficacy and tolerability of carbamazepine for agitation and aggression in dementia. Am J Psychiatry 1998;155:54-61.
98. Olin JT, Fox LA, Pawluczyk S, Taggart NA, Schneider LS. A pilot randomized trial of carbamazepine for behavioral symptoms in treatment-resistant outpatients with Alzheimer's disease. Am J Geriatr Psychiatry 2001;9:4000-5.
99. Jeste DV, Eastham JH, Lohr JB, Salzman C. Treatment of disordered behavior and psychosis. In: Salzman C, ed. Clinical geriatric psychopharmacology. 3rd ed. Baltimore, MD: Williams & Wilkins, 1998:106-49.
100. Lott AD, McElroy SL, Keys MA. Valproate in the treatment of behavioral agitation in elderly patients with dementia. J Neuropsychiatry Clin Neurosci 1995;7:314-19.
101. Herrmann N. Valproic acid treatment of agitation in dementia. Can J Psychiatry 1998;43:69-72.
102. Kunik ME, Puryear L, Orengo CA, Molinari V, Workman RH. The efficacy and tolerability of divalproex sodium in elderly demented patients with behavioral disturbances. Int J Geriatr Psychiatry 1998;13:29-34.
103. Mellow AM, Carlos Solano-Lopez, Davis S. Sodium valproate in the treatment of behavioral disturbance in dementia. J Geriatr Psychiatry Neurol 1993;6:205-9.
104. Haas S, Vincent K, Holt J, Lippman S. Divalproex: a possible treatment alternative for demented, elderly, aggressive patients. Ann Clin Psychiatry 1997;9:145-7.
105. Porsteinsson AP, Tariot PN, Erb R, Gaile S. An open trial of valproate for agitation in geriatric neuropsychiatric disorders. Am J Geriatr Psychiatry 1997;5:344-51.
106. Narayan M, Nelson JC. Treatment of dementia with behavioral disturbance using divalproex or a combination of divalproex and a neuroleptic. J Clin Psychiatry 1997;58:351-4.
107. Horne M, Lindley SE. Divalproex sodium in the treatment of aggressive behavior and dysphoria in patients with organic brain syndromes. J Clin Psychiatry 1995;56:430-1.
108. Sival RC, Haffmans PM, Jansen PA, Duursma SA, Eikelenbloom P. Sodium valproate in the treatment of aggressive behavior in patients with dementia: a randomized placebo controlled clinical trial. Int J Geriatr Psychiatry 2002;17:579-85.
109. Megna JL, Devitt PJ, Sauro MD, Dewan MJ. Gabapentin's effect on agitation in severely and persistently mentally ill patients. Ann Pharmacother 2002;36:12-6.
110. Ryback R, Ryback L. Gabapentin for behavioral dyscontrol [Letter]. Am J Psychiatry 1995;152:1399.
111. Dallocchio C, Buffa C, Mazzarello P. Combination of donepezil and gabapentin for behavioral disorders in Alzheimer's disease. J Clin Psychiatry 2000;61:64.
112. Herrmann N, Lanctot K, Myszak M. Effectiveness of gabapentin for the treatment of behavioral disorders in dementia. J Clin Psychopharmacol 2000;20:90-3.
113. Low RA, Brandes M. Gabapentin for the management of agitation. J Clin Psychopharmacol 1999;19:482-3.
114. Regan WM, Gordon SM. Gabapentin for behavioral agitation in Alzheimer's disease. J Clin Psychopharmacol 1997;17:59-60.
115. Hawkins JW, Tinklenberg JR, Sheikh JI, Peyser CE, Yesavage JA. A retrospective chart review of gabapentin for the treatment of aggressive and agitated behavior in patients with dementias. Am J Geriatr Psychiatry 2000;8:221-5.
116. Roane DM, Feinberg TE, Meckler L, Miner CR, Scicutella A, Rosenthal RN. Treatment of dementia-associated agitation with gabapentin. J Neuropsychiatry Clin Neurosci 2000;12:40-3.
117. Millwer LJ. Gabapentin for treatment of behavioral and psychological symptoms of dementia. Ann Pharmacother 2001;35:427-31.
118. Devarajan S, Durson SM. Aggression in dementia with lamotrigine treatment [Letter]. Am J Psychiatry 2000;157:1178.
119. Tekin S, Aykut-Bingol C, Tanridag T, Aktan S. Antiglutamatergic therapy in Alzheimer's disease-effects of lamotrigine. Short communication. J Neural Transmission 1998;105:295-303.
120. Chatterjee CR, Ringold AL. A case report of reduction in alcohol craving and protection against alcohol withdrawal by gabapentin [Letter]. J Clin Psychiatry 2000;60:617.
121. Longo LP. Divalproex sodium for alcohol withdrawal and relapse prevention: a case report. J Clin Psychiatry 2000;61:947-8.
122. Reoux JP, Saxon AJ, Malta CA, Baer JS, Sloan KL. Divalproex sodium in alcohol withdrawal: a randomized double-blind placebo-controlled clinical trial. Alcohol Clin Exp Res 2001;25:1324-9.
123. Bastie Y. Suppression des crises d'epilepsie du sevrage par le depakine dans les cures de desintoxication ethylique. Ann Med Psychol (Paris) 1970;2:400-4.
124. Minuk GY, Rockman GE, Duerksen DR, Borrett G, Hoeschen L. The use of sodium valproate in the treatment of alcoholism. J Addict Dis 1995;14:67-74.
125. Lambie DG, Johnson RH, Vijayasenan ME, Whiteside EA. Sodium valproate in the treatment of the alcohol withdrawal syndrome. Aust N Z J Psychiatry 1980;14:213-5.
126. Rosenthal RN, Perkel C, Singh P, Anand O, Miner CR. A pilot open randomized trial of valproate and phenobarbital in the treatment of acute alcohol withdrawal. Am J Addict 1998;7:189-97.
127. Hammer BA, Brady KT. Valproate treatment of alcohol withdrawal and mania [Letter]. Am J Psychiatry 1996;153:1232.
128. Roberts JM, Malcolm R, Santos AB. Treatment of panic disorder and comorbid substance abuse with divalproex sodium [Letter]. Am J Psychiatry 1994;151:15-21.
129. Brady KT, Sonne S, Lydiard RB. Valproate treatment of comorbid panic disorder and affective disorders in two alcoholic patients. J Clin Psychopharmacol 1994;14:81-2.
130. McElroy SL, Keck PE, Lawrence JM. Treatment of panic disorder and benzodiazepine withdrawal with valproate. J Neuropsychiatry Clin Neurosci 1991;3:232-3.
131. Hillbom M, Tokola R, Kuusela V, Karkkainen P, Kalli-Lemma L, Pilke A, et al. Prevention of alcohol withdrawal seizures with carbamazepine and valproic acid. Alcohol 1989;6:223-6.
132. Myrick H, Malcolm R, Brady KT. Gabapentin treatment of alcohol withdrawal. Am J Psychiatry 1998;155:1632.
133. Bonnet U, Banger M, Lewele FM, Maschke M, Kowalski T, Gastpar M. Treatment of alcohol withdrawal syndrome with gabapentin. Pharmacopsychiatry 1999;32:107-9.
134. Bozikas V, Petrikis P, Gamvrula K, Savvidou I, Karavatos A. Treatment of alcohol withdrawal with gabapentin. Prog Neuropsychopharmacol Biol Psychiatry 2002;26:197-9.
135. Karam-Hage, Brower KJ. Gabapentin treatment for insomnia with alcohol dependence. Am J Psychiatry 2000;157:151.
136. Raby WN. Gabapentin therapy for cocaine cravings [Letter]. Am J Psychiatry 2000;157:2058-9.
137. Markowitz JS, Finkenbine R, Myrucj G, King L, Carson WH. Gabapentin: abuse in a cocaine user: implications for treatment? [Letter]. J Clin Psychopharmacol 1997;17:423-4.
138. Myrick H, Henderson S, Brady KT, Malcolm R. Gabapentin in the treatment of cocaine dependence: a case series. J Clin Psychiatry 2001;62:19-23.
139. Brady KT, Sonne SC, Anton R, Ballenger JC. Valproate in the treatment of acute bipolar affective episodes complicated by substance abuse: a pilot study. J Clin Psychiatry 1995;56:118-21.
140. Albanese MJ, Clodfetter RC, Khantzian EJ. Divalproex sodium in substance abusers with mood disorder. J Clin Psychiatry 2000;61:916-21.
141. Lima AR, Lima MS, Soares BG, Farrell M. Carbamazepine for cocaine dependence. Cochrane Database Syst Rev 2002;2:CD002023.
142. Brown ES, Nejtek VA, Perantie DC, Orsulak PJ, Bobadilla L. Lamotrigine in patients with bipolar disorder and cocaine dependence. J Clin Psychaitry 2003;64:197-201.
143. Pollack MH, Matthews J, Scott EL. Gabapentin as a potential treatment for anxiety disorders [Letter]. Am J Psychiatry 1988;155:992-3.
144. de-Paris F, Busnello JV, Vianna MR, Salgueiro JB, Quevedo J, Izquierdo I, et al. The anticonvulsant compound gabapentin possesses anxiolytic but not amnesic effects in rats. Behav Pharmacol 2000;11:169-73.
145. Lum M, Fontaine R, Elie R, Ontiveros A. Probable interaction of sodium divalproex with benzodiazepines. Prog Neuropsychopharmacol Biol Psychiatry 1991;15:269-73.
146. Keck PE, McElroy SL, Tugrul KC, Bennett SA, Smith JM. Antiepileptic drugs for the treatment of panic disorder. Neuropsychopharmacology 1993;27:150-3.
147. Primeau F, Fontaine R, Beauclair L. Valproic acid and panic disorder. Can J Psychiatry 1990;35:248-50.
148. Keck PE, McElroy SL, Friedman LM. Valproate and carbamazepine in the treatment of panic and posttraumatic stress disorders, withdrawal states, and behavioral dyscontrol syndromes. J Clin Psychopharmacol 1992;12(suppl):36S-41S.
149. Lum M, Fontaine R, Elie R, Ontiveros A. Divalproex sodium's antipanic effect in panic disorder: a placebo-controlled study. Biol Psychiatry 1990;27:164A-165A.
150. Roy-Byrne PP, Ward NG, Donnelly PJ. Valproate in anxiety and withdrawal syndromes. J Clin Psychiatry 1989;50(suppl 3):44-8.
151. Woodman CL, Noyes R. Panic disorder: treatment with valproate. J Clin Psychiatry 1994;55:134-6.
152. Baetz M, Bowen RC. Efficacy of divalproex sodium in patients with panic disorder and mood instability who have not responded to conventional therapy. Can J Psychiatry 1998;43:73-7.
153. Keck PE, McElroy SL, Tugrul KC, Bennett JA, Smith JMR. Valproate treatment of panic disorder and lactate-induced panic attacks. Biol Psychiatry 1993;33:542-6.
154. Ontiveros A, Fontaine R. Sodium valproate and clonazepam for treatment-resistant panic disorder. J Psychiatry Neurosci 1992;17:78-80.
155. Marazziti D, Cassano GB. Valproic acid for panic disorder associated with multiple sclerosis. Am J Psychiatry 1996;153:6-7.
156. Pande AC, Pollack MH, Crockett J, Greiner M, Chouinard G, Lydiard RB, et al. Placebo-controlled study of gabapentin of panic disorder. J Clin Psychopharmacol 2000;20:467-71.
157. Layton ME, Friedman SD, Dager SR. Brain metabolic changes during lactate-induced panic: effects of gabapentin treatment. Depress Anxiety 2001;14:251-4.
158. Zwanger P, Baghai TC, Schule C, Minov C, Padberg F, Moller HJ, et al. Tiagabine improves panic and agoraphobia in panic disorder patients. J Clin Psychiatry 2001;62:656-7.
159. Zwanzger P, Baghai TC, Schuele C, Ströhle A, Padberg F, Kathmann N, et al. Vigabatrin decreases cholecystokinintetrapeptide (CCK-4) induced panic in healthy volunteers. Neuropsychopharmacology 2001;25:699-703.
160. Pande AC, Davidson JR, Jefferson JW, Janney CA, Katzelnick DJ, Weisler RH, et al. Treatment of social phobia with gabapentin: a placebo-controlled study. J Clin Psychopharmacol 1999;19:341-8.
161. Jefferson JW. Benzodiazepines and anticonvulsants for social phobia (social anxiety disorder). J Clin Psychiatry 2001;62(suppl 1):50-3.
162. Garcia-Campayo J, Sanz-Carrillo C. Gabapentin for the treatment of patients with somatization disorder. J Clin Psychiatry 2001;62:474.
163. Shapira NA, Goldsmith TD, McElroy SL. Treatment of binge-eating disorder with topiramate: a clinical case series. J Clin Psychiatry 2000;61:368-72.
164. Appolinario JC, Coutinho W, Fontenelle L. Topiramate for binge-eating disorder [Letter]. Am J Psychiatry 2001;158:967-8.
165. Felstrom A, Blackshaw S. Topiramate for bulimia nervosa with bipolar II disorder [Letter]. Am J Psychiatry 2002;159:1246-7.
166. Colom F, Fieta E, Benabarre A, Martinez-Aran A, Reinares M, Corbella B, et al. Topiramate abuse in a bipolar patients with an eating disorder [Letter]. J Clin Psychiatry 2001;62:475-6.
167. McElroy SL, Arnold LM, Shapira NA, Keck PE Jr, Rosenthal NR, Karim MR, et al. Topiramate in the treatment of binge eating disorder associated with obesity: a randomized, placebo-controlled trial. Am J Psychiatry 160;2:255-61.
168. Schweitzer E, Rickels K, Case WG, Greenblatt DJ. Carbamazepine treatment in patients discontinuing long-term benzodiazepine therapy: effects on withdrawal severity and outcome. Arch Gen Psychiatry 1991;48:448-52.
169. Rickels K, Case WG, Schweizer E. Withdrawal from benzodiazepines. In: Hindmarch I, Beaumont G, Brandon S, Leonard BE, eds. Benzodiazepines: current concepts-biological, clinical and social perspectives. West Sussex, England: John Wiley & Sons, 1990:199-210.
170. Galpern WR, Miller LG, Greenblatt DJ, Szabo GK, Browne TR, Shader RI. Chronic benzodiazepine administration. IX. Attenuation of alprazolam discontinuation effects by carbamazepine. Biochem Pharmacol 1991; 42(suppl):S99-104.
171. Apelt S, Emrich HM. Sodium valproate in benzodiazepine withdrawal. Am J Psychiatry 1990;147:950-1.
172. Motohashi M. GABA receptor alterations after chronic lithium: in comparison with carbamazepine and sodium valproate. Presented at the 17th annual Collegium Internationale Neuropsychopharmacologicum Congress, September 1990, Kyoto, Japan.
173. Liljequist S, Engel JA. Reversal of the anti-conflict action of valproate by various GABA and benzodiazepine antagonists. Life Sci 1984;34:2525-33.
174. Deltito JA. Valproate pretreatment for difficult-to-treat patient with OCD [Letter]. J Clin Psychiatry 1994;55:500.
175. Cora-Locatelli G, Greenberg BD, Martin JD, Murphy DL. Valproate monotherapy in an SRI-intolerant OCD patient [Letter]. J Clin Psychiatry 1998;59:82.
176. Pallanti S, Quercioli L, Sood E, Hollander E. Lithium and valproate treatment of pathological gambling: a randomized single-blind study. J Clin Psychiatry 2002;63:559-64.
177. Valela D, Black DW. Pedophilia treated with carbamazepine and clonazepam. Am J Psychiatry 2002;159:1245-6.
178. Lipper S, Davidson JR, Grady TA, Edinger JD, Hammett EB, Mahorney SL, et al. Preliminary study of carbamazepine in post-traumatic stress disorder. Psychosomatics 1986;27:849-54.
179. Wolf ME, Alavi A, Mosniam AD. Posttraumatic stress disorder in Vietnam veterans: clinical and EEG findings. Possible therapeutic effects of carbamazepine. Biol Psychiatry 1988;23:642-4.
180. Fesler FA. Valproate in combat-related posttraumatic stress disorder. J Clin Psychiatry 1991;52:361-4.
181. Ford N. The use of anticonvulsant in posttraumatic stress disorder: case study and overview. J Trauma Stress 1996;9:857-63.
182. Berigan TR, Holzgang A. Valproate as an alternative in posttraumatic stress disorder: a case report. Mil Med 1995;160:318.
183. Brodsky L, Doerman AL, Palmer LS, Slade GF, Munasifi FA. Posttraumatic stress disorder: an eclectic approach. Int J Psychosom 1990;37:89-95.
184. Clark RD, Canive JM, Calais LA, Qvalis CR, Tuason VB. Divalproex in posttraumatic stress disorder: an open-label clinical trial. J Trauma Stress 1999;12:395-40.
185. Szymanski HV, Olympia J. Divalproex in posttraumatic stress disorder. Am J Psychiatry 1991;148:1086-7.
186. Hamner MB, Brodrick PS, Labbate LA. Gabapentin in PTSD: a retrospective, clinical series of adjunctive therapy. Ann Clin Psychiatry 2001;13:141-6.
187. Berlant J, and van Kammen DP. Open-label topiramate as primary or adjunctive therapy in chronic civilian posttraumatic stress disorder: a preliminary report. J Clin Psychiatry 2002;63:15-20.
188. Hertzberg MA, Butterfield MI, Feldman ME, Beckham JC, Sutherland SM, Connor KM, et al. A preliminary study of lamotrigine for the treatment of posttraumatic stress disorder. Biol Psychiatry 1999;45:1226-9.
189. Andre V, Ferrandon A, Marescaux C, Nehlig A. Vigabatrin protects against hippocampal damage but is not antiepileptogenic in the lithium-pilocarpine model of temporal lobe epilepsy. Epilepsy Res 200;47:99-117.
190. Deltito J, Martin L, Riefkohl K, Austria B, Kissilenko A, Corless C, et al. Do patients with borderline personality disorder belong to the bipolar spectrum? J Affect Disord 2001;67:221-8.
191. Rifkin A, Quitkin F, Curillo C. Lithium carbonate in emotionally unstable character disorder. Arch Gen Psychiatry 1972;27:519-23.
192. Links PS, Steiner M, Boiago I, Erwin D. Lithium therapy for borderline patients: preliminary findings. J Clin Psychopharmacol 1990;4:173-81.
193. Cowdry RW, Gardner DL. Pharmacotherapy of borderline personality disorder: alprazolam, carbamazepine, trifluoperazine, and tranylcypromine. Arch Gen Psychiatry 1988;45:111-9.
194. De la Fuente J, Lotstra F. A trial of carbamazepine in borderline personality disorder. Eur Neuropsychopharmacol 1994;4:479-86.
195. Grossman R. Psychopharmacologic treatment of patients with borderline personality disorder. Psychiatr Ann 2002;32:357-70.
196. Townsend MH, Cambra KM, Barbee JG. Treatment of borderline personality disorder with mood instability with divalproex sodium: series of ten cases. J Clin Psychopharmacol 2001;21:249-51.
197. Frankenburg FR, Zanarini MC. Divalproex sodium treatment of women with borderline personality disorder and bipolar II disorder: a double-blind placebo-controlled pilot study. J Clin Psychiatry 2002;63:442-6.
198. Hollander E, Allen A, Lopez RP, Bienstock CA, Grossman R, Siever LJ, et al. A preliminary double-blind, placebo-controlled trial of divalproex sodium in borderline personality disorder. J Clin Psychiatry 2001;62:199-203.
199. Hollander E, Tracy KA, Swann AC, Coccaro EF, McElroy SL, Wozniak P, et al. Neuropsychopharmacol 2003;6:1186-97.
200. Stein DJ, Simeon D, Frenkel M, Islam MN, Hollander E. An open trial of valproate in borderline personality disorder. J Clin Psychiatry 1995;56:506-10.
201. Wilcox J. Divalproex sodium in the treatment of aggressive behavior. An Clin Psychiatry 1994;6:17-20.
202. Kavoussi RJ, Coccaro EF. Divalproex sodium for impulsive aggressive behavior in patients with personality disorder. J Clin Psychiatry 1998;59:676-80.
203. Pinto OC, Akiskal HS. Lamotrigine as a promising approach to borderline personality: an open case series without concurrent DSM-IV major mood disorder. J Affect Disord 1998;51:333-43.
204. Sierra M, Phillips ML, Lambert MV, Senior C, David AS, Krystal JH. Lamotrigine in the treatment of depersonalization disorder [Letter]. J Clin Psychiatry 62;10:826-7.